Back to News
Market Impact: 0.2
Natera Partners With Angiex For CtDNA Monitoring In Solid Tumor Trial Using Signatera
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsTechnology & Innovation
Natera said it will collaborate with Angiex to use its Signatera circulating tumor DNA test for ctDNA monitoring in a Phase I study of AGX101, an investigational nuclear-delivered therapy. The agreement supports ongoing clinical validation of Signatera in oncology trials and is a modest positive incremental development, though no financial impact was disclosed in the excerpt.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.18
Ticker Sentiment
NTRA0.30
More News
- Better Biotechnology ETF: First Trust FBT vs. VanEck BBH
- Musk says Terrafab chip factory could outperform rivals despite challenges
- Stocks saw new highs and big declines: How the volatile AI trade moved last week's market
- Will Warner Bros. kill Skydance — or will David Ellison kill Warner Bros?
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary